Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 5, 2009, Pages 377-380

  Nielsen, Vance G ^a,b,c   Kirklin, James K ^b   George, James F ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Kentucky   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Carbon monoxide; Carbon monoxide releasing molecule; Coagulation; Thrombelastography

Indexed keywords

CARBON MONOXIDE; DIMER; INFUSORIAL EARTH; RUTHENIUM DERIVATIVE; THROMBOPLASTIN; TRISCARBONYLDICHLORORUTHENIUM; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CONTROLLED STUDY; HUMAN; KINETICS; PLASMA; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBUS;

BLOOD COAGULATION; CARBON MONOXIDE; DIATOMACEOUS EARTH; DRUG EVALUATION, PRECLINICAL; FACTOR XIII DEFICIENCY; HEMOSTATICS; HUMANS; ORGANOMETALLIC COMPOUNDS; PLASMA; THROMBELASTOGRAPHY;

EID: 68149089854     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832ca3a3     Document Type: Article

References (14)

1. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 2005; 57:585-630.
2. True AL, Olive M, Boehm M, San H, Westrick RJ, Raghavachari N, et al. Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. Circ Res 2007; 101:893-901.
3. Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res 2002; 90:e17-e24.
4. Motterlini R. Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, antiischaemic and anti-inflammatory activities. Biochem Soc Trans 2007; 35:1142-1146.
5. Motterlini R, Mann BE, Foresti R. Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin Investig Drugs 2005; 14:1305-1318.
6. Megias J, Busserolles J, Alcaraz MJ. The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells. Br J Pharm 2007; 150:977-986.
7. Brune B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol 1987; 32:497-504.
8. Brune B, Schmidt KU, Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem 1990; 192:683-688.
9. Chlopicki S, Olszanecki R, Marcinkiewicz E, Lomnicka M, Motterlini R. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase. Cardiovasc Res 2006; 71:393-401.
10. Dong D, Chen C, Huang W, Chen Y, Zhang X, Li Z, et al. Tricarbonyldichlororuthenium (II) dimer (CORM2) activates nonselective cation current in human endothelial cells independently of carbon monoxide releasing. Eur J Pharmacol 2008; 590:99-104.
11. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography1: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005; 49:222-231.
12. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17:75-81.
13. Nielsen VG, Gurley WQ, Burch TM. Impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004; 99:120-123.
14. Nielsen VG, Audu P, Cankovic L, Lyerly RT III, Steenwyk BL, Armstead VE, et al. Qualitative thrombelastographic method of detection of tissue factor in human plasma. Anesth Analg 2007; 104:59-64.